Correlation of blood glucose and prostatic-related parameters in patients with prostate enlargement

Abstract

Enlarged prostate, either in benign prostatic hyperplasia or prostate cancer is the predominant urological disease affecting older men. Metabolic syndrome including high blood glucose was considered to take part in the development of prostate enlargement, although their association is still unclear. This study aims to investigate the correlation between blood glucose with prostatic-related parameters. A cross-sectional study was conducted involving 91 men with prostate enlargement from Urology Polyclinic, Tabanan Hospital, Bali Province, Indonesia. Prostatic-related parameters collected include patient’s international prostate symptoms score using the questionnaire, prostate-specific antigen and random blood glucose analysis from serum blood sample, and prostate volume determined with transabdominal ultrasonography. Patient’s mean age was 65.4 ± 10 years, mean prostate volume 52.7 ± 26 ml, mean prostate-specific antigen (PSA) 9.2 ± 17 ng/ml, mean international prostatic symptoms score (IPSS) 14.31 ± 7.1, mean random blood glucose 121.1 ± 40.5 mg/dl. This study found weak positive correlation between random blood glucose and prostate volume (r=0.269; p=0.01). PSA and prostate volume showed moderate positive correlation (r=0.365; p<0.001). No correlation between random blood glucose with PSA or IPSS was found in this study. This study found random blood glucose has positive correlation with prostate volume. We recommend enhancing blood glucose control to prevent the progress of prostate enlargement.

Keywords

• blood glucose
• prostate
• prostate-specific antigen
• urology

References

1. Lim K Bin. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017 Jul;4(3):148–51.
2. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014 Apr;30(2):170–6.
3. Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015 Jun;6(6):850–67.
4. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020 Mar;10(1):107–11.
5. Liu C, Yuan Y-C, Guo M-N, Xin Z, Chen G-J, Bentley AR, et al. Incidence of Type 1 Diabetes May Be Underestimated in the Chinese Population: Evidence From 21.7 Million People Between 2007 and 2017. Diabetes Care. 2021 Nov;44(11):2503–9.
6. Wu Y, Ding Y, Cao QF, Qian SB, Wang C, Duan HQ, et al. The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia. World J Urol. 2020 Nov;38(11):2923–31.
7. Chen Z, Miao L, Gao X, Wang G, Xu Y. Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes. Int J Clin Exp Med. 2015;8(7):11289–94.
8. Qu X, Huang Z, Meng X, Zhang X, Dong L, Zhao X. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients. Int Urol Nephrol. 2014 Mar;46(3):499–504.

9. Yim SJ, Cho YS, Joo KJ. Relationship between metabolic syndrome and prostate volume in Korean men under 50 years of age. Korean J Urol. 2011 Jun;52(6):390–5.
10. Breyer BN, Sarma A V. Hyperglycemia and insulin resistance and the risk of BPH/LUTS: an update of recent literature. Curr Urol Rep. 2014 Dec;15(12):462.
11. Kahal H, Halama A, Aburima A, Bhagwat AM, Butler AE, Graumann J, et al. Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects. Sci Rep. 2020;10(1):4750.
12. Nugroho EA, Kurniawan R. Association between Hyperglycemia and Prostate Volume in Patients with Benign Prostate Enlargement : A Hospital Case-Control Study. J Biomed Transl Res [Internet]. 2017 Dec 31;3(2):46. Available from: https://ejournal2.undip.ac.id/index.php/jbtr/article/view/1971
13. Ferreira FT, Daltoé L, Succi G, Cunha F, Ferreira JM, Lorenzetti F, et al. Relation between glycemic levels and low tract urinary symptoms in elderly. aging male Off J Int Soc Study Aging Male. 2015 Mar;18(1):34–7.
14. Duarsa GWK, Dau DO, Pramana IBP, Tirtayasa PMW, Yudiana IW, Santosa KB, et al. Risk Factors for Prostate Volume Progression After Prostate-Transurethral Resection. Res Reports Urol [Internet]. 2020 May [cited 2022 Oct 1];Volume 12:175–8. Available from: /pmc/articles/PMC7211307/
15. Al-Khalil S, Ibilibor C, Cammack JT, de Riese W. Association of prostate volume with incidence and aggressiveness of prostate cancer. Res reports Urol. 2016;8:201–5.
16. Kim EH, Brockman JA, Andriole GL. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol. 2018 Jan;5(1):28–32.
17. Xu C, Xu Y, Shen Z, Zhou H, Xiao J, Huang T. Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia. Int Urol Nephrol. 2018 Apr;50(4):611–7.
18. Wang Z, Olumi AF. Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation. 2011;82(4–5):261–71.